Novo Nordisk Expands Weight Loss Research with Embark Biotech Acquisition

Novo Nordisk has acquired Embark Biotech for €15 million upfront and up to €456 million in milestones. The acquisition provides Novo Nordisk with a lead program for obesity and other cardiometabolic diseases, targeting appetite suppression, increased energy expenditure, and enhanced insulin sensitivity.